Dr. med. Susan Foller

Studium Humanmedizin an der Johann-Wolfgang-Goethe-Universität Frankfurt am Main 2000-2006

Klinik und Poliklinik für Urologie am Universitätsklinikum Dresden 2006-2010

Klinik und Poliklinik für Urologie am Universitätsklinikum Jena 2010-2024

Voigt S, Hüttig F, Koch R. et al. Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benign prostate hyperplasia? Prostate. 2011 Sep;71(12):1325-31. doi: 10.1002/pros.21349.
Epub 2011 Feb 9. DOI 10.1007/s00735-022-1581-0

Roediger J, Hessenkemper, W, Bartsch S, Manvelyan M, Huettner SS, Liehr T, Esmaeili, M, Foller S, Petersen I, Grimm MO, Baniahmad A.  Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway.  Mol Cancer. 2014 Sep 12;13:214. doi: 10.1186/1476-4598-13-214.#

T Franiel, P Asbach, U. ,Teichgräber, B Hamm, S Foller. Prostate Imaging-An Update. Röfo. 2015 Sep;187(9):751-9. doi: 10.1055/s-0035-1553162. 

Drozdz S, Schwedas M, Salz, H, Foller S, Wendt TG. Prostate cancer treated with image-guided helical TomoTherapy® and image-guided LINAC-IMRT : Correlation between high-dose bladder volume, margin reduction, and genitourinary toxicity

FOLLER, S.; LEUCHT, K.; MARC-OLIVER, G. Frühe Stadien – kurative, operative Konzepte bei Urothelkarzinomen. TumorDiagnostik & Therapie. 45(02): 85-89 p. 2024. Strahlenther Onkol. 2016, Apr;192(4):223-31. doi: 10.1007/s00066-015-0935-y. Epub 2016 Jan 7

Grimm MO, Oppel-Heuchel H, Foller S.  [Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors : Immune-mediated side effects]. Urologe A. 2018 May;57(5):543-551. doi: 10.1007/s00120-018-0635-1.

S Foller, H Oppel-Heuchel, M-O Grimm. [Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression]. Urologe A. 2018 Nov;57(11):1316-1325. doi: 10.1007/s00120-018-0788-y.

Grimm MO, Foller S. [Immunotherapy for renal cell carcinoma - current status]. Aktuelle Urol. 2018 Apr;49(2):187-191. doi: 10.1055/a-0581-4451. Epub 2018 Mar 27.

Szabados B, Foller S, Schulz, GB, Staehler M, Grimm MO, Stief CG, Casuscelli J. [Follow-up of renal cell carcinoma in a nonmetastatic stage]. Urologe A. 2019 Jan;58(1):65-76. doi: 10.1007/s00120-018-0823-z. 

Grimm MO, Leucht K, Foller S, Grünwald V. [Risk-adapted therapy for metastatic renal cell carcinoma]. Urologe A. 2020 Feb;59(2):155-161. doi: 10.1007/s00120-020-01131-x.

Grimm MO, Leucht K, Grünwald V, Foller S. New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. J Clin Med. 2020 Feb 19;9(2):565. doi: 10.3390/jcm9020565

Butea-Bocu M, Foller S, Gleisner J, Kahlmeyer A, Karstedt H, Kirschner- Hermanns R, Liebald T, Linne C, Manseck A, Moll V, Otto U, Piotrowski A, Schorn A, Stein J, Wagner A, Wiedemann A. S2k-Leitlinie Hilfsmittelberatung. Aktuelle Urol. 2021 Apr;52(2):168-180. doi: 10.1055/a-1293-2831. Epub 2021 Apr 1.

Leucht K, Foller S, Grimm MO. [Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer]. Urologe A. 2021 Nov;60(11):1400-1408. doi: 10.1007/s00120-021-01681-8. Epub 2021 Oct 28. 

Grimm MO, Leucht K, Foller S. Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma. J Clin Med. 2021 Nov 16;10(22):5339. doi: 10.3390/jcm10225339. 

Grimm MO, Gottschlich T, Ali N, Foller S, Leucht K. [Side effects of immune checkpoint inhibitor treatment of urological tumors]  Urologe A. 2021 Jun;60(6):803- 815. doi: 10.1007/s00120-021- 01550-4. Epub 2021 Jun 8.

Elterman DS, Foller S, Ubrig B, Kugler A, Misrai V, Porreca A, Abt D, Zorn KC, Bhojani N, Kriteman L, Mehan R, McDonald M, Kaplan SA. Focal bladder neck cautery associated with low rate of post-Aquablation bleeding. Can J Urol. 2021 Apr;28(2):10610-10613.

Jahn L, Rüster C, Schlosser M, Winkler Y, Foller S, Grimm MO, Wolf G, Busch M. Rate, Factors, and Outcome of Delayed Graft Function After Kidney Transplantation of Deceased Donors. Transplant Proc. 2021 Jun;53(5):1454-1461. doi: 10.1016/j.transproceed.2021.01.0 06. Epub 2021 Feb 18.

Grimm MO, Gottschlich T, Ali N, Foller S, Leucht K. Rate, Factors, and Outcome of Delayed Graft Function After Kidney Transplantation of Deceased Donors. Urologe A. 2021 Jul 5. doi: 10.1007/s00120-021-01590-w. Online ahead of print.

Schomburg L, Malouhi A, Grimm MO, Ingwersen M, Foller S, Leucht K, Teichgräber U. iRECIST-based versus non-standardized free text reporting of CT scans for monitoring metastatic renal cell carcinoma: a retrospective comparison. 

Manseck A, Piotrowski A, Butea-Bocu M, Foller S, Gleissner J, Kahlmeyer A, Karstedt H, Kirschner-Hermanns R, Liebald T, Linné C, Moll V, Otto U, Schorn A, Stein J, Wagner A, Wiedemann A. Qualifizierte Beratung für Inkontinenzhilfsmittel: Das
Verbesserungspotenzial ist erheblich. Procare. 2022;27(6-7):12-17. doi: 10.1007/s00735-022-1581-0. Epub 2022 Sep 9.

Leucht K, Ali N, Foller S, Grimm MO. Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma. Cancers (Basel). 2022 Sep 8;14(18):4369. doi: 10.3390/cancers14184369.

BJ, Zimmermann U, Grün CB, Baretton GB, Schmitz M, Foller S, Leucht K, Schostak M, Zengerling F, Schumacher U, Loidl W, Meran J. Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma. J Clin Oncol. 2022 Jul 1;40(19):2128-2137. doi: 10.1200/JCO.21.02631. Epub 2022 Mar 11

Wolf CPJG, Rachow T, Ernst T, Hochhaus A, Zomorodbakhsch B, Foller S, Rengsberger M, Hartmann M, Hübner J. Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements. J Cancer Res Clin Oncol. 2022
Feb;148(2):461-473. doi: 10.1007/s00432-021-03625-3. Epub 2021 Apr 17.

Theurich AT, Leistritz L, Leucht K, Franiel T, Teichgräber U, Foller S, Grimm MO. Influence of Prostate Artery Embolization on Different Qualities of Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction. Eur Urol Focus. 2022 Sep;8(5):1323-1330. doi: 10.1016/j.euf.2022.01.011. Epub 2022 Feb 4.

Manseck A, Piotrowski A, Butea MC, Foller S, Gleissner J, Kahlmeyer A, Karstedt H, Kirschner- Hermanns R, Liebald T, Linné C, Moll V, Otto U, Schorn A, Stein J, Wagner A, Wiedemann A. Urologe A. 2022 Jan;61(1):3-12. doi: 10.1007/s00120-021-01721-3.

Schomburg L, Malouhi A, Grimm MO, Ingwersen M, Foller S, Leucht K, Teichgräber U. iRECIST-based versus non-standardized free text reporting of CT scans for monitoring metastatic renal cell carcinoma: a retrospective comparison.  J Cancer Res Clin Oncol. 2022 Aug;148(8):2003-2012. doi: 10.1007/s00432-022-03997-0. Epub 2022 Apr 14.

Wolf CPJG, Rachow T, Ernst T, Hochhaus A, Zomorodbakhsch B, Foller S, Rengsberger M, Hartmann M, Huebner J. Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment. J Cancer Res Clin Oncol. 2022 May;148(5):1123-1135. doi: 10.1007/s00432-021-03675-7. Epub 2021 Jul 6.

Grimm MO, Foller S, Leeder M, Leucht K. Erratum zu: Antikörper-Wirkstoff-Konjugate als neues Wirkprinzip in der Uroonkologie.  Urologie. 2023 Oct;62(10):1095. doi: 10.1007/s00120-023-02178-2.

Grimm MO, Foller S, Leeder M, Leucht K. [Antibody-drug conjugates as new therapeutic agents in uro-oncology] Urologie. 2023 Jul;62(7):679-684. doi: 10.1007/s00120-023-02118-0. Epub 2023 Jun 9.

Grimm MO, Foller S, Leucht K. [Combination therapy with poly(adenosine diphosphate-ribose) polymerase (PARPi) and androgen receptor signaling pathway (ARPi) inhibitors for metastatic castration-resistant prostate cancer] Urologie. 2023 Dec;62(12):1269-1280. doi:10.1007/s00120-023-02230-1. Epub 2023 Nov 17.

Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F.  Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, singlearm, phase 2 trial. Lancet Oncol. 2023 Apr;24(4):347-359. doi: 10.1016/S1470-2045(23)00053-0. Epub 2023 Feb 28.

Winkens T, Berger FP, Foller S, Greiser J, Groeber S, Grimm MO, Freesmeyer M, Kuehnel C. 67 Ga-PSMA I&T for Radioguided Surgery of Lymph Node Metastases in Patients With Biochemical Recurrence of Prostate Cancer. Clin Nucl Med. 2023 Jul 1;48(7):600-607. doi: 10.1097/RLU.0000000000004668 . Epub 2023 May 5.

Aubrechtová Dragounová K, Ryabchykov O, Steinbach D, Recla V, Lindig N, González Vázquez MJ, Foller S, Bauer M, Bocklitz TW, Popp J, Rödel J, Neugebauer U. Identification of bacteria in mixed infection from urinary tract of patient's samples using Raman analysis of dried droplets. Analyst. 2023 Aug 7;148(16):3806-3816. doi: 10.1039/d3an00679d.

Grimm MO, Esteban E, Barthélémy P, Schmidinger M, Busch J, Valderrama BP, Charnley N, Schmitz M, Schumacher U, Leucht K, Foller S, Baretton G, Duran I, de Velasco G, Priou F, Maroto P, Albiges L; TITAN-RCC study group. Tailored immunotherapy approach with nivolumab Lancet Oncol 10.1002/pros.21349 with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2023 Nov;24(11):1252-1265. doi: 10.1016/S1470-2045(23)00449-7. Epub 2023 Oct 13.

FRANKE, K.; FOLLER, S.; ROSERO MORENO, M. E.; ALI, N. et al. Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC. Cancers (Basel), 16, n. 12, Jun 20 2024.

FRÖLICH, U. M.; LEUCHT, K.; GRIMM, M. O.; FOLLER, S. Complications of Tumor Nephrectomy with and Without Tumor Thrombus in the Vena Cava, Recorded with the Clavien-Dindo Classification: A Matched-Pair Analysis. Cancers (Basel), 16, n. 20, Oct 18 2024.

GRIMM, M. O.; SCHOSTAK, M.; GRÜN, C. B.; LOIDL, W. et al. Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol, 10, n. 6, p. 755-764, Jun 01 2024a.

GRIMM, M. O.; SCHOSTAK, M.; GRÜN, C. B.; LOIDL, W. et al. Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol, 10, n. 6, p. 755-764, Jun 01 2024b.

HILSER, T.; DARR, C.; NIEGISCH, G.; SCHNABEL, M. J. et al. Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project. Cancers (Basel), 16, n. 17, Aug 28 2024.

SCHMIDT, J.; YAKAC, A.; PETERS, R.; FRIEDERSDORFF, F. et al. Radical Prostatectomy in Kidney Transplant Recipients-A Multicenter Experience. Eur Urol Open Sci, 67, p. 45-53, Sep 2024. J Cancer Res Clin Oncol. 2022 Aug;148(8):2003-2012. doi: 10.1007/s00432-022-03997-0. Epub 2022 Apr 14.